Christian D. Fankhauser

@DrSpratticus @dr_coops @Uroweb @BogdanaSchmidt @ChapinMD @wandering_gu @qdtrinh @jeshoag @SFreedlandMD @EUplatinum @UrologyUS For most radical prostatectomies? Multiport remains more efficient. The Single Port has less force than multiport systems — a weaker robot by design. But that may actually be its hidden advantage: it slows the surgeon down slightly, potentially making the operation more precise?

Urology community Help teach us non-surgeons the benefit of single port and continence outcomes. Is this something that improves outcomes? @dr_coops @Uroweb @BogdanaSchmidt @ChapinMD @wandering_gu @qdtrinh @jeshoag @SFreedlandMD @EUplatinum @UrologyUS

@DrSpratticus @dr_coops @Uroweb @BogdanaSchmidt @ChapinMD @wandering_gu @qdtrinh @jeshoag @SFreedlandMD @EUplatinum @UrologyUS From one of the highest-volume single-port institutions in Europe — and having performed every operation single-port for ~2 years — my honest take: SP makes a real difference in <10% of cases. Think dense adhesions or true multi-quadrant work.

@DrSpratticus @dr_coops @ChapinMD @urotoday @UroOnc @Uroweb @wandering_gu @BogdanaSchmidt @CanesDavid @DrMLChua @HimanshuNagarMD @AmarUKishan @piet_ost @alison_tree @declangmurphy @uroegg Great discussion, but a simple DRE before pelvic surgery to assess rectal/vaginal involvement should be standard practice. Every surgeon who has ever faced a difficult pelvis knows this instinctively. This is like assessing parachutes 🪂 — you don’t need an RCT to know it matters

@dr_coops @ChapinMD @urotoday @UroOnc @Uroweb @wandering_gu @BogdanaSchmidt @CanesDavid @DrMLChua @HimanshuNagarMD @AmarUKishan @piet_ost @alison_tree @declangmurphy @uroegg So for patients with already confirmed PCa post biopsy and who have or will have MRI, why is DRE recommended? I understand pre biopsy and during screening, but post diagnosis and MRI I don’t see a reason to recommend it as it won’t change management.

#EAU26 DRE not recommended for asymptomatic men. What are people’s thoughts on need for routine DRE in era of MRI? @ChapinMD @urotoday @UroOnc @Uroweb @wandering_gu @BogdanaSchmidt @CanesDavid @DrMLChua @HimanshuNagarMD @AmarUKishan @piet_ost @alison_tree @declangmurphy

This is one of the best pieces I’ve read in a long time. Many thanks to @anish_koka for this superb piece and thoughtful recounting. Those who really know @VPrasadMDMPH know he will do even more good and rise even higher.

Our @JCO_ASCO commentary is out today: “BCG and Beyond: Is Systemic Immunotherapy for BCG-Naïve NMIBC Progress or Overreach?” Systemic IO has now entered the BCG-naïve high-risk NMIBC space. The signal is real. The interpretation must be disciplined. Thread below. 🧵 #BladderCancer #GU26 #EAU26 @AndreaNecchi @BrigidaMaiorano @shilpaonc @UrogerliMD @pjhensley11 @spsutkaMD @AmirHorowitz @IBCG_BladderCA @JCO_ASCO #OncSurgery

in J Urol this month a decision analysis of PLND during RP Take home message: benefits of PLND outweigh risk for most patients. auajournals.org/doi/10.1097/JU… @VickersBiostats @UrologyMSK #prostatecancer @Uroweb @AmerUrological

@LauraBukavinaMD @FabianAschwand1 is looking at this prospectively

ctDNA can be the ultimate gray zone in BCG-unresponsive #bladdercancer: >NED on scopes + scans after gem/doce, but ctDNA+ Imaging lags behind biology 🚩With no bladder disease, cystectomy doesn’t “fix” it .. This is 95% certain early nodal disease? Is diagnostic LND the answer for diagnosis when imaging fails? Thoughts??

@YAUpenile_tesCa @WalterCazzaniga Keep on rocking

A great meeting filled with new ideas and valuable contributions to research in penile and testis cancers. #EMUC25 Warm welcome to the new members of our group! 👋 Congratulations to @WalterCazzaniga on his new role as group leader, and a heartfelt thank You to @CDFankhauser for his tremendous work, dedication, and mentorship so far. 🙏 #ManyThanks We are proud of our joint work and of what we are building together 🌟 “Alone we can do so little; together we can do so much.” #Urology #PenileCancer #TestisCancer #EAU #YAU #Research #Collaboration #Oncology

@lee_c_zhao @NYUUrology @AmrElbakryUro @SocietyGURS Incr animation🤗Link not working?

Devastating radiation complications typically means urinary diversion— our latest work details robotic free flap urethroplasty @NYUUrology showcasing how free tissue transfer can salvage the outlet @AmrElbakryUro @SocietyGURS authors.elsevier.com/c/1m1ODKZx3joPu

It's out 🚀 Our multicentric collaboration just got published in @BJUIjournal. Huge thanks to all our incredible co-authors and the @YAUpenile_tesCa who made this work possible. Read it here: bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj… @MaartenAlbersen, @Brouwer_MD_PhD, @BE_Ayres, @CDFankhauser

@BogdanaSchmidt @UtahUrology @auawest @UtahUroRes Sounds interesting, have you published ur technique or could you share this talk?

Fantastic @UtahUrology resident Lindsey Wright presenting on the Utah Arch technique for catheterizable stoma at @auawest 🌟 feasible 🌟 teachable @UtahUroRes

New out in @TheLancetOncol with Ted Schaeffer: pubmed.ncbi.nlm.nih.gov/41038181/ "Revisiting prostate cancer active surveillance candidacy" A close look at the fallacy and risks of active surveillance (AS) in unselected intermediate risk (IR) men. @wandering_gu @TylerSbrt

@spsutkaMD @cgratzke @AgostinoMattei @LauraBukavinaMD @Tilki_De Thank you so much for your amazing presentations in lucerne 🤗 @UniLuzern @KantonsspitalLU

Tremendous gratitude to the organizers of #Brennpunkt #Urologie in beautiful Luzern @cgratzke @AgostinoMattei! Thank you for the invitation to join you, talk a little about #Prehab, & the chance to spend some time with such great friends! @LauraBukavinaMD @Tilki_De @CDFankhauser

Ever wondered whether elective scrotal surgery really needs perioperative antibiotic prophylaxis (PAP)? 🤔 Our new @wjurol study found a 3× lower SSI rate (12% vs 4%; p=0.058) and fewer readmissions (26% vs 16%; p=0.13) with PAP. Although not statistically significant, PAP may still help protect selected high-risk patients from postoperative infections. In an era of rising antimicrobial resistance, routine prophylaxis warrants careful reconsideration! 💊 🔗 Full text – rdcu.be/eIo6F @MaximeValle5 @StanglFabian @endouro @AgostinoMattei @CDFankhauser

Would surgery add survival benefit to the systemic treatment in patients with oligometastatic prostate cancer ? A new data highlights this; 👉Adding radical prostatectomy to best systemic therapy cut 5-yr cancer-specific mortality from 23% to 13% (HR 0.39, p=0.045). Early termination of study, OS benefit not statistically significant; 14% had major surgery complications. 👉Supports further efforts for local therapy + systemic treatment in oligomet prostate cancer. doi.org/10.1016/j.euru… @EUplatinum @OncoAlert @ONCOassist @APCCC_Lugano

@RoboticsUrology @HUMCUrology @SimplyUroMD @MSBillah_md Agree that SP is in the toolkit but this is certainly a tricky case acc to imaging. Is this a pick up lymphadenectomy or a spec template? Would love to see post op pics of resected area if u may share them too

SP robot – Final incision photo. Had to extend slightly beyond the usual 3 cm due to specimen size. Photo shared with patient’s permission. @HUMCUrology @SimplyUroMD @MSBillah_md

A 17-year-old male with testicular mixed germ cell cancer, post-chemotherapy, demonstrates no significant change in mass size. Imaging is provided below. Please select the most appropriate management approach. See image in comments.

Still leading the pack! @EUplatinum

@JoshMeeks provides an amazing overview of the significant data emerging in the BCG-unresponsive NMIBC space, focusing on the CIS cohorts. We also discuss the recent ODAC decision on UGN-102 for lower risk disease which was recently FDA approved. spotifycreators-web.app.link/e/szAiuFvyaUb

@Uromigos @AttardLab @PCFnews @charlesryanmd @ProstateUK @Prof_Nick_James @neerajaiims @TDorffOnc @Silke_Gillessen @DRathkopf Incredible podcast! 🙏 I'm begging for a follow-up podcast with Peter Wild (Frankfurt Pathology) discussing genetic testing & genomic scar analyses +- functional assays to predict PARPi response @tompowles1 @brian_rini

The highlight of #ASCO25 was the AMPLITUDE trial presented by @AttardLab on PARPi in HRR altered mHSPC. Listen to our podcast discussing these practice-changing data! spotifycreators-web.app.link/e/77hbNX73YTb